NPM1 and acute myeloid leukemia: The earlier dose escalation phase Ia (KMT2Ar, NPM1-m, and other signatures included), phase Ib dose validation (KMT2Ar or NPM1-m), and phase Ib dose expansion cohort (NPM1-m only) included heavily pretreated AML patients, and 25% of them had prior HSCT.